用Stilbenes针对神经系统疾病:弥合临床前临床差距
Md Zamshed Alam Begh1, Jishan Khan2, Mehrukh Zehravi3
1Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka 1207, Bangladesh.
International journal of biological sciences
|November 4, 2024
概括
斯蒂尔因通过调节细胞通路,对神经系统疾病 (NDs) 显示神经保护潜力. 需要进一步的临床研究来证实它们在特定患者群体的治疗有效性.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生化学
背景情况:
- 像阿尔茨海默病,帕金森病和中风等神经系统疾病 (NDs) 缺乏有效的治疗方法.
- 斯蒂尔,天然的多,表现出神经保护性质.
- ресвератрол,piceatannol 和 pterostilbene 是具有潜在治疗益处的关键 stilbenes.
研究的目的:
- 为了探索 stilbenes 在神经疾病中的神经保护潜力.
- 审查史蒂尔本疗效的临床前和临床证据.
- 突出需要进一步的临床研究对NDS的stilbenes.
主要方法:
- 对神经退行症中斯蒂尔本机制的临床前研究的综述.
- 对用于大脑健康的stilbene补充剂的临床试验数据的分析.
- 检查 stilbenes 调节的细胞通路,包括氧化应激,神经发生和线粒体功能.
主要成果:
- 临床前数据强烈支持stilbenes调节神经退行途径的能力.
- Resveratrol在减少氧化损伤和增强大脑功能方面具有显著的益处.
- 关于白醇的临床研究产生了不同的结果,表明需要更多的研究.
结论:
- 斯蒂尔作为神经保护剂在神经疾病中表现有前途.
- 目前对stilbenes的临床证据有限,特别是除了白醇之外的化合物.
- 更全面和有针对性的临床研究对于确定特定患者群体的治疗疗效至关重要.
相关概念视频
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K


